Open Journal Systems

Effect of Docetaxel and Cisplatin Chemotherapy Combined with Intensity-modulated Radiotherapy in the Treatment of Postoperative Recurrence of Esophageal Cancer and Its Effect on Serum Tumor Markers

Tianliang Zhao (The People's Hospital of Zhangye City,Zhangye City,Gansu Province,China)
Weinian Kang (The People's Hospital of Wuwei City,Wuwei City,Gansu Province,China)

Abstract


Objective. To investigate the effect of docetaxel and cisplatin combined with intensity-modulated radiotherapy in the treatment of postoperative recurrence of esophageal cancer and the content of tumor markers in serum. Methods. According to simple randomization method, 60 patients with postoperative recurrence of esophageal cancer admitted from February 2018 to September 2019 were divided into control group (n = 30 cases) and observation group (n = 30 cases). All patients received IMRT. Fluorouracil + cisplatin was used in the control group and docetaxel + cisplatin was used in the observation group. After 2 courses of continuous treatment, the therapeutic effect, serum tumor marker content and adverse reactions were compared between the two groups. Results. After treatment, the effective rate of observation group was higher than control group, and the difference was statistically significant (P < 0.05).The contents of carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and carbohydrate antigen 19-9 (CA19-9) in observation group were lower than those in control group, and the difference was statistically significant (P < 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant (P < 0.05). Conclusion. Docetaxel and cisplatin combined with intensemodulated radiotherapy for postoperative recurrence of esophageal cancer can improve the therapeutic effect, inhibit the malignant degree of tumor, and reduce the incidence of adverse reactions.


Keywords


Postoperative recurrence of esophageal cancer; Fluorouracil; Docetaxel; Cisplatin; Chemotherapy; Radiation therapy

Full Text:

PDF

References


Zhou H R, Zhang Y X, Li Y J. The clinical efficacy and safety of paclitaxel combined with cisplatin and docetaxel combined with carboplatin in the treatment of advanced ovarian cancer

Kawamura M, Kawamura M, Kawamura M, et al. The role of cancer in the pathogenesis of cancer: a review [J]. J Cancer Res, 2012, 34(11):1888-1890. Combination of anticancer drugs in the treatment of advanced gastric cancer patients

[J]. J Clin Rep Drug Use, 2019,12 (29): 45-46. (in Chinese)

Tan Linshen, Piao Ying, Zheng Zhendong. Clinical observation of docetaxel combined with cisplatin plus Shenyi capsule in the treatment of advanced gastric cancer [J]. Journal of Clinical Military Medicine,

,47 (9) : 905-907.

Ye FM, Zhang J, Cao XM, et al. Continuity of self-management in coronary heart disease

The influence of PCI in patients with postoperative rehabilitation [J]. Journal of henan medical research, 2019, 28 (9) : 1572-1574.

DAI T T, WANG W W, TONG Y S, et al. Clinical efficacy of docetaxel combined with cisplatin combined chemoradiotherapy and radiotherapy in the treatment of elderly non-operative esophageal squamous cell carcinoma [J]. Journal of Applied Cancer, 2019,34 (3):417-420.

Huang Hao, Luo Jieyan, Li Lu. Clinical efficacy and prognosis of docetaxel combined with three-dimensional conformal radiotherapy for advanced esophageal cancer [J]. Journal of Applied Cancer, 2019,34 (2):235-237.

Wu Jin, Zhou Lihua, Qi Liwei. Effects of docetaxel and nedaplatin combined radiotherapy on serum indexes and tumor circulating cells in elderly patients with esophageal cancer [J]. Chinese Journal of Gerontology, 2018,38 (24): 5999-5952.

YANG W, CHENG M, YU L J, et al. Effects of docetaxel combined with apatinib on immune function and quality of life in patients with advanced esophageal cancer [J]. Journal of Clinical Military Medicine, 2018,46 (11):1369-1370.



DOI: http://dx.doi.org/10.30564/amor.v6i3.275

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Tianliang Zhao

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.